Showing results (91-100 of 212) with videos related to
Sort By:
Pageof 22
Oncotarget|March 25, 2014
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trialAline Renneville, Raouf Ben Abdelali, Sylvie Chevret, et al.Leukemia|July 14, 2020
A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosisJonathan Bond, Aleksandra Krzywon, Ludovic Lhermitte, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association groupNicolas Boissel, Olivier Nibourel, Aline Renneville, et al.Haematologica|August 5, 2018
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Cécile Pautas, Christine Terré, et al.British Journal of Haematology|September 3, 2025
Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemiaAugustin Boudry, Laure Goursaud, Delphine Lebon, et al.Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.American Journal of Hematology|June 11, 2013
Outcome of older patients with acute myeloid leukemia in first relapseClémentine Sarkozy, Claude Gardin, Nathalie Gachard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemiaHélène Lapillonne, Aline Renneville, Anne Auvrignon, et al.Blood|May 15, 2004
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 studySylvie Castaigne, Sylvie Chevret, Eric Archimbaud, et al.Blood|March 28, 2013
MYD88 L265P mutation in Waldenstrom macroglobulinemiaStéphanie Poulain, Christophe Roumier, Audrey Decambron, et al.Pageof 22